All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Corporate BondsHigh yield

Opioid maker Grünenthal readies high yield debut months after freeze-out

pills adobe stock 575x375 pharmaceuticals

Grünenthal, the German pharmaceutical firm which specialises in painkillers, is looking to refinance its debt with an inaugural high yield bond, just two months after buyers reportedly shunned the company over ESG concerns around opioid manufacturing.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree